文献速递浆细胞疾病

蛋白酶体β2位点抑制剂使骨髓瘤细胞对免疫蛋白酶体抑制剂敏感

An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
PubMed 文献 · Blood Adv · 2018-01-01

多发性骨髓瘤(MM)最终对硼替佐米、卡非佐米和伊沙佐米耐药,免疫蛋白酶体表达在耐药患者中升高。β5i特异性抑制剂ONX-0914在MM细胞系中表现出与卡非佐米和硼替佐米相似的细胞毒性;β2位点抑制剂LU-102显著增强MM细胞系和原代细胞对ONX-0914的敏感性;ONX-0914在体外和体内与所有FDA批准的蛋白酶体抑制剂协同作用。

要点

  • ONX-0914在MM细胞系中的细胞毒性与卡非佐米和硼替佐米相似。
  • 干扰素-γ增加免疫蛋白酶体表达,增加对ONX-0914的敏感性,但不增加对卡非佐米的敏感性。
  • β2位点抑制剂LU-102显著增强MM细胞系和原代细胞对ONX-0914的敏感性。

核心结论

  • 免疫蛋白酶体抑制剂(目前正在临床试验中用于治疗自身免疫性疾病)也应考虑用于治疗MM。

研究设计与样本

  • 本研究为体外和体内实验研究,使用MM细胞系和原代细胞,未报告样本量。

主要发现

  • 药理学相关浓度的β5i特异性抑制剂ONX-0914在MM细胞系中表现出与卡非佐米和硼替佐米相似的细胞毒性。
  • 干扰素-γ增加免疫蛋白酶体表达,增加对ONX-0914的敏感性,但不增加对卡非佐米的敏感性。
  • β2位点抑制剂LU-102显著增强MM细胞系和原代细胞对ONX-0914的敏感性。
  • ONX-0914在体外和体内与所有FDA批准的蛋白酶体抑制剂在MM中协同作用。

临床怎么用

  • 作者认为,免疫蛋白酶体抑制剂(目前正在临床试验中用于治疗自身免疫性疾病)也应考虑用于治疗MM。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Proteasome inhibitors bortezomib, carfilzomib and ixazomib (approved by the US Food and Drug Administration [FDA]) induce remissions in patients with multiple myeloma (MM), but most patients eventually become resistant. MM and other hematologic malignancies express ubiquitous constitutive proteasomes and lymphoid tissue-specific immunoproteasomes; immunoproteasome expression is increased in resistant patients. Immunoproteasomes contain 3 distinct pairs of active sites, β5i, β1i, and β2i, which are different from their constitutive β5c, β1c, and β2c counterparts. Bortezomib and carfilzomib block β5c and β5i sites. We report here that pharmacologically relevant concentrations of β5i-specific inhibitor ONX-0914 show cytotoxicity in MM cell lines similar to that of carfilzomib and bortezomib. In addition, increasing immunoproteasome expression by interferon-γ increases sensitivity to ONX-0914 but not to carfilzomib. LU-102, an inhibitor of β2 sites, dramatically sensitizes MM cell lines and primary cells to ONX-0914. ONX-0914 synergizes with all FDA-approved proteasome inhibitors in MM in vitro and in vivo. Thus, immunoproteasome inhibitors, currently in clinical trials for the treatment of autoimmune diseases, should also be considered for the treatment of MM.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Downey-Kopyscinski S, Daily EW, Gautier M, et al. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors. Blood Adv. 2018. PMID: 30266819. doi:10.1182/bloodadvances.2018016360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。